George R. Painter

7.2k citations

98 papers · 3.9k indexed · 3 hit papers · h-index 36

Infectious Diseases top 0.5%
Epidemiology top 1%
Molecular Biology top 10%
Virology top 0.5%
Genetics top 5%

Co-authors: Michael G. Natchus Wendy Painter Alice Robertson Alexander A. Kolykhalov Karl Y. Hostetler Gregory R. Bluemling Bernhard Lampert Berton C. Pressman
Topics: HIV/AIDS drug development and treatment (29 papers)HIV Research and Treatment (21 papers)Herpesvirus Infections and Treatments (17 papers)
Cited by: Virology Infectious Diseases Epidemiology
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States United Kingdom Germany

In The Last Decade

George R. Painter

96 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

2021 274 citations Wendy Painter, Wayne Holman et al. profile →
Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

2019 255 citations Maria L. Agostini, Andrea J. Pruijssers et al. Journal of Virology profile →
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

2019 233 citations Märt Toots, Jeong-Joong Yoon et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by George R. Painter

Since Specialization

Citations

This map shows the geographic impact of George R. Painter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George R. Painter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George R. Painter more than expected).

Fields of papers citing papers by George R. Painter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George R. Painter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George R. Painter. The network helps show where George R. Painter may publish in the future.

Co-authorship network of co-authors of George R. Painter

This figure shows the co-authorship network connecting the top 25 collaborators of George R. Painter. A scholar is included among the top collaborators of George R. Painter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George R. Painter. George R. Painter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19 2025 ·Clinical and Translational Science ·Akshita Chawla,Ruthie Birger,Brian M. Maas,Youfang Cao,Hong Wan,Julie Strizki,Arthur Fridman,Amanda Paschke,Carisa De Anda,Wei Gao,Matthew L. Rizk,Wendy Painter,Wayne Holman,(unknown),George R. Painter,Julie A. Stone	0
2	Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine 2025 ·mBio ·Jonna B. Westover,(unknown),(unknown),Kevin W. Bailey,(unknown),(unknown),(unknown),Alexander A. Kolykhalov,Michael G. Natchus,George R. Painter,Brian B. Gowen	0
3	Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models 2023 ·Nature Communications ·Robert M. Cox,Carolin M. Lieber,Josef D. Wolf,Amir-Hossein Karimi,Nicole A. P. Lieberman,Zachary M. Sticher,Pavitra Roychoudhury,(unknown),(unknown),Michael G. Natchus,George R. Painter,Alexander A. Kolykhalov,Alexander L. Greninger,Richard K. Plemper	18
4	The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection 2022 ·Antiviral Research ·Gregory R. Bluemling,(unknown),Michael G. Natchus,Wendy Painter,Sabue Mulangu,Mark A. Lockwood,Abel De La Rosa,Trevor Brasel,Jason E. Comer,Alexander N. Freiberg,Alexander A. Kolykhalov,George R. Painter	9
5	Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19 2021 ·Current Opinion in Virology ·George R. Painter,Michael G. Natchus,Oren J. Cohen,(unknown),Wendy Painter	112
6	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epitheliabreakdown → 2019 ·Science Translational Medicine ·Märt Toots,Jeong-Joong Yoon,Robert M. Cox,M. N. Hart,Zachary M. Sticher,Negar Makhsous,Roland Plesker,(unknown),Prabhakar Reddy,Deborah G. Mitchell,Ryan C. Shean,Gregory R. Bluemling,Alexander A. Kolykhalov,Alexander L. Greninger,Michael G. Natchus,George R. Painter,Richard K. Plemper	233
7	The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection 2019 ·Antiviral Research ·George R. Painter,Richard A. Bowen,Gregory R. Bluemling,(unknown),(unknown),(unknown),David B. Guthrie,Michael Hager,(unknown),Mark A. Lockwood,Deborah G. Mitchell,Michael G. Natchus,Zachary M. Sticher,Alexander A. Kolykhalov	81
8	Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistancebreakdown → 2019 ·Journal of Virology ·Maria L. Agostini,Andrea J. Pruijssers,James D. Chappell,Jennifer Gribble,Xiaotao Lu,Erica L. Andres,Gregory R. Bluemling,Mark A. Lockwood,Timothy P. Sheahan,Amy Sims,Michael G. Natchus,Manohar Saindane,Alexander A. Kolykhalov,George R. Painter,Ralph S. Baric,Mark R. Denison	255
9	β- d - N ⁴ -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome 2017 ·Journal of Virology ·Nadya Urakova,Valeriya Kuznetsova,David K. Crossman,Arpine Sokratian,David B. Guthrie,Alexander A. Kolykhalov,Mark A. Lockwood,Michael G. Natchus,Michael R. Crowley,George R. Painter,Elena I. Frolova,Ilya Frolov	148
10	Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems 2016 ·Antiviral Research ·Stephen R. Welch,Lisa Wiggleton Guerrero,Ayan K. Chakrabarti,Laura K. McMullan,Mike Flint,Gregory R. Bluemling,George R. Painter,Stuart T. Nichol,Christina F. Spiropoulou,César G. Albariño	57
11	Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans 2011 ·Viruses ·Amanda D. Rice,Mathew M. Adams,Bernhard Lampert,Scott A. Foster,Randall Lanier,Alice Robertson,George R. Painter,Richard W. Moyer	36
12	Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies 2010 ·The Journal of Infectious Diseases ·Debra C. Quenelle,(unknown),Deborah J. Collins,(unknown),George R. Painter,Earl R. Kern	61
13	In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents 1996 ·Antiviral Research ·M H St Clair,Judith Millard,John P. Rooney,Margaret Tisdale,N. R. Parry,Brian M. Sadler,Martin Blum,George R. Painter	65
14	Recombinant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Is Heterogeneous 1996 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·(unknown),Lois L. Wright,J L Martin,(unknown),Paul H. Ray,George R. Painter,Phillip A. Furman	6
15	524W91. Anti-HIV, Anti-hepatitis B virus 1995 ·Drugs of the Future ·George R. Painter,Marty St. Clair,(unknown),(unknown),(unknown),P A Furman	5
16	Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy 1995 ·The Journal of Infectious Diseases ·(unknown),S. Pazhanisamy,David Porter,Judith A. Partaledis,Roger D. Tung,George R. Painter	63
17	Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label 1993 ·Biochemistry ·Nancy Cheng,B M Merrill,George R. Painter,Lloyd Frick,Phillip A. Furman	23
18	A Comparison of the Conformations of the 5′-Triphosphates of Zidovudine (AZT) and Thymidine Bound to HIV-1 Reverse Transcriptase 1993 ·Biochemical and Biophysical Research Communications ·George R. Painter,Ann Aulabaugh,C. Webster Andrews	31
19	Crosslinking of substrates occurs exclusively to the p66 subunit of heterodimeric HIV-1 reverse transcriptase 1991 ·Biochemical and Biophysical Research Communications ·Nancy Cheng,George R. Painter,Phillip A. Furman	35
20	The effects of lipid composition on the binding of lasalocid A to small unilamellar vesicles 1990 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·(unknown),George R. Painter	4

About George R. Painter

George R. Painter is a scholar working on Virology, Infectious Diseases and Epidemiology, having authored 98 papers that have together received 3.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (21 papers) and Herpesvirus Infections and Treatments (17 papers). The work is most often cited by research in Virology (1.0k citations), Infectious Diseases (2.1k citations) and Epidemiology (1.6k citations). George R. Painter has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Michael G. Natchus, Wendy Painter, Alice Robertson, Alexander A. Kolykhalov, Karl Y. Hostetler, Gregory R. Bluemling, Bernhard Lampert, Berton C. Pressman, Lawrence C. Trost and R. Mark L. Buller. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact